BioSpace News Archive

BPL Plasma, a global leader in the plasma collection industry, launched a COVID-19 convalescent plasma collection program in the hope of accelerating a treatment for the deadly coronavirus that has impacted millions worldwide.

Zyla Life Sciences, a commercial stage life sciences company, announced that its 2020 first quarter financial results will be released on May 15, 2020.

ImmunoGen today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2020.

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, May 7, 2020, at 8:00 a.m. ET to report its first quarter 2020 financial results and other business updates. A live webcast will be available under “News & Events” in the Investors & Media section of the company’s website at orchard-tx.com. The conference call can be accessed by

Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, announced that its CEO, Dr Jonathan Allis, has been appointed as Chair of the UK Rapid Testing Consortium for COVID-19 by the UK Department of Health and Social Care.

Co-Diagnostics, Inc. (Nasdaq: CODX) , a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today released COVID-19 test performance data demonstrating 100% sensitivity and 100% specificity, the metrics used to define accuracy in molecular diagnostics testing.

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Mon., May 11, 2020 at 4:30 p.m. ET to discuss its financial results for the first quarter ended Mar. 31, 2020. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor confere

Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the first quarter ended March 31, 2020, prior to the market open on Thursday, May 7, 2020. Company management will host a conference call and webcast to discuss its financial results and provide

VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced an agreement regarding its corporate debt with IEH Biopharma LLC, which holds a principal amount of approximately $170.1 million of the Company’s Convertible Senior Notes with a maturity date of May 1, 2020. The Company does not currently have the ability to pay the principal amount of the Convertible Senior Notes held by IEH Biopharma. Under the terms of

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that it is continuing discussions with Mylan N.V. (NASDAQ: MYL) regarding whether or not Mylan plans to move forward with the biosimilar to BOTOX® program. As previously disclosed, the expe